News From NYTimes that hospital groups may band together to get generic drugs on the cheap is hurting $TEVA and $VRX stock. But it's $ENDP that will get hurt the most.Endo Internatoinal - ENDP: $ENDP, Endo International plc / H1 Valeant's generic unit is less strategic in its turnaround: $BHC, Bausch Health Companies Inc. / H1 Xifaxan from Salix, dermatology, and B+L eye care will give Valeant's revenue a boost.$TEVA, meanwhile is fine. Stock will hold $20. $TEVA, Teva Pharmaceutical Industries Limited / H1 Valeant Stock will hold $20/share in the next month. Agree or disagree?This group is 800+ members strong. 1000 next. Join us. Sign in and vote.